Download PDF
Hamostaseologie 2008; 28(S 01): S113
DOI: 10.1055/s-0037-1621604
Original article
Schattauer GmbH

Inzidenz des erworbenen VWS bei 41 Patienten mit myeloproliferativen Erkrankungen

Incidence of acquired von Willebrand disease in 41 patients suffering from myeloproliferative disorders
C. von Auer
1   III. Medizinische Klinik für Hämatologie und Onkologie, J. Gutenberg Universitätsklinik Mainz
,
C. Flick
1   III. Medizinische Klinik für Hämatologie und Onkologie, J. Gutenberg Universitätsklinik Mainz
,
I. Scharrer
1   III. Medizinische Klinik für Hämatologie und Onkologie, J. Gutenberg Universitätsklinik Mainz
› Author Affiliations
Further Information

Publication History

Publication Date:
04 January 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • Literatur

  • 1 Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006; 43 (01) 48-S58.
    CrossrefPubMedGoogle Scholar
  • 2 Federici AB. Therapeutic approaches to acquired von Willebrand syndrome. Exp Opin Invest Drugs 2000; 9 (02) 347-354.
    CrossrefPubMedGoogle Scholar
  • 3 Federici AB, Jacob H. et al. Acquired von Wille-brand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345-349.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Murugesan G, Aboudola S, Szpurka H. et al. Identification of the JAK2 V617F mutation in chronic myeloproliferaative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006; 125: 625-633.
    CrossrefPubMedGoogle Scholar
  • 5 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
    CrossrefPubMedGoogle Scholar
  • 6 Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F ea. Am Soc Hematol 2006; 240-245.
    PubMedGoogle Scholar
  • 7 Budde U. et al. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1984; 68: 981-985.
    PubMedGoogle Scholar